Maxim Group Cuts Indaptus Therapeutics (NASDAQ:INDP) Price Target to $5.00

Indaptus Therapeutics (NASDAQ:INDP) had its price objective decreased by equities research analysts at Maxim Group from $8.00 to $5.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective would suggest a potential upside of 344.44% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Indaptus Therapeutics in a research note on Wednesday, October 16th.

Indaptus Therapeutics Price Performance

Shares of Indaptus Therapeutics stock opened at $1.13 on Wednesday. The stock has a market capitalization of $11.48 million, a price-to-earnings ratio of -0.66 and a beta of 1.45. Indaptus Therapeutics has a 12 month low of $1.03 and a 12 month high of $3.10. The firm’s fifty day simple moving average is $1.32 and its 200-day simple moving average is $1.83.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. Analysts anticipate that Indaptus Therapeutics will post -1.79 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is currently owned by institutional investors.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.